TUĞLULAR, A. T. Et Al. 2022. Post-authorization safety of lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma in Turkey. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA .

TUĞLULAR, A. T., PEHLİVAN, M., SÖNMEZ, M., Hacioglu, S. K., SAYDAM, G., Ayyildiz, O., ... KAYNAR, L.(2022). Post-authorization safety of lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma in Turkey. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA .

TUĞLULAR, AYŞE Et Al. "Post-authorization safety of lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma in Turkey," CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , 2022

TUĞLULAR, AYŞE T. Et Al. "Post-authorization safety of lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma in Turkey." CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , 2022

TUĞLULAR, A. T. Et Al. (2022) . "Post-authorization safety of lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma in Turkey." CLINICAL LYMPHOMA MYELOMA & LEUKEMIA .

@article{article, author={AYŞE TÜLİN TUĞLULAR Et Al. }, title={Post-authorization safety of lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma in Turkey}, journal={CLINICAL LYMPHOMA MYELOMA & LEUKEMIA}, year=2022}